Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T82494
(Former ID: TTDI01634)
|
|||||
| Target Name |
T-cell receptor (TCR)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 15 Target-related Diseases | + | ||||
| 1 | Graft-versus-host disease [ICD-11: 4B24] | |||||
| 2 | Psoriasis [ICD-11: EA90] | |||||
| 3 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| 4 | Bladder cancer [ICD-11: 2C94] | |||||
| 5 | Head and neck cancer [ICD-11: 2D42] | |||||
| 6 | Liposarcoma [ICD-11: 2B59] | |||||
| 7 | Melanoma [ICD-11: 2C30] | |||||
| 8 | Multiple myeloma [ICD-11: 2A83] | |||||
| 9 | Multiple sclerosis [ICD-11: 8A40] | |||||
| 10 | Neuroendocrine carcinoma [ICD-11: 2C34] | |||||
| 11 | Ovarian cancer [ICD-11: 2C73] | |||||
| 12 | Synovial sarcoma [ICD-11: 2B5A] | |||||
| 13 | Acute myeloid leukaemia [ICD-11: 2A60] | |||||
| 14 | Liver cancer [ICD-11: 2C12] | |||||
| 15 | Myelodysplastic syndrome [ICD-11: 2A37] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 8 Clinical Trial Drugs | + | ||||
| 1 | IR502 | Drug Info | Phase 2 | Psoriatic disorder | [2] | |
| 2 | RGI-2001 | Drug Info | Phase 2 | Graft-versus-host disease | [3] | |
| 3 | SAR444200 | Drug Info | Phase 2 | Aggressive cancer | [4] | |
| 4 | MAGE-A10 TCR | Drug Info | Phase 1/2 | Bladder cancer | [5] | |
| 5 | NY-ESO-TCR | Drug Info | Phase 1/2 | Melanoma | [6] | |
| 6 | TOL-101 | Drug Info | Phase 1/2 | Multiple sclerosis | [7] | |
| 7 | AFP TCR | Drug Info | Phase 1 | Hepatocellular carcinoma | [5] | |
| 8 | BPX-701 | Drug Info | Phase 1 | Acute myeloid leukaemia | [5], [6] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | IR502 | Drug Info | [8] | |||
| 2 | RGI-2001 | Drug Info | [9] | |||
| Immunomodulator | [+] 3 Immunomodulator drugs | + | ||||
| 1 | MAGE-A10 TCR | Drug Info | [6] | |||
| 2 | AFP TCR | Drug Info | [6] | |||
| 3 | BPX-701 | Drug Info | [6] | |||
| CAR-T-Cell-Therapy | [+] 1 CAR-T-Cell-Therapy drugs | + | ||||
| 1 | NY-ESO-TCR | Drug Info | [6] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355. | |||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008880) | |||||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 4 | ClinicalTrials.gov (NCT05450562) A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors. U.S.National Institutes of Health. | |||||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 7 | ClinicalTrials.gov (NCT01154387) Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection. U.S. National Institutes of Health. | |||||
| REF 8 | WO patent application no. 2004,0677,06, Production of multimeric proteins. | |||||
| REF 9 | Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68. | |||||
| REF 10 | Clinical pipeline report, company report or official report of Sanofi | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.